The emergency department is a pressure cooker where stressed patients, psychological distress and violence combine into a ...

The emergency department is a pressure cooker where stressed patients, psychological distress and violence combine into a ...

Stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days and starting ...

Bayer AG’s oral factor XIa inhibitor asundexian significantly reduced ischemic stroke by 26% in patients following a noncardioembolic ischemic stroke or high-risk transient ischemic attack in the ...

Global phase 3 OCEANIC-STROKE randomized 12,327 patients to asundexian 50 mg daily vs placebo on background antiplatelets, with follow-up to 31 months. Treatment effects were consistent across TOAST ...

Bayer presents positive data on asundexian, which shows superior efficacy with no added bleeding risk, boosting hopes for ...

For patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack, asundexian, a factor XIa inhibitor, reduced risk for secondary stroke with no excess risk for any bleeding vs ...

An investigational anti-clotting medication, asundexian, demonstrated a reduction in the risk of a second ischemic ...

German drugmaker Bayer (BAYN: DE) has revealed positive late-stage results for its investigational once-daily oral ...

Doctors know that once someone has had a stroke, the risk of a second one is much higher. In fact, nearly one in four stroke ...

A recent observational study has highlighted the clinical value of transthoracic echocardiography (TTE) in patients evaluated ...

The factor XIa inhibitor asundexian reduced recurrent ischemic stroke without increasing major or minor bleeding in patients ...